A 4-week, dose-ranging study comparing the efficacy, safety and tolerability of latanoprost 75, 100 and 125 μg/mL to latanoprost 50 μg/mL (xalatan) in the treatment of primary open-angle glaucoma and ocular hypertension

Table 2 Change in IOP (mmHg) from baseline to week 4 (worse eye, ANCOVA, PP population)

	Latanoprost concentration (μg/mL)
	50	75	100	125
N	69	66	71	68
8 a.m. IOP
LS mean change (mmHg)*	−10.13	−9.59	−10.02	−9.06
Adjusted difference in LS mean ± SEM^†		0.54 ± 0.46	0.12 ± 0.45	1.07 ± 0.45
(90% CI)		(−0.22, 1.29)	(−0.63, 0.86)	(0.32, 1.82)
p-value^‡		0.879	0.602	0.990
4 p.m. IOP
LS mean change (mmHg)*	−8.90	−8.29	−8.81	−8.34
Adjusted difference in LS mean ± SEM^†		0.60 ± 0.47	0.09 ± 0.45	0.55 ± 0.46
(90% CI)		(−0.16, 1.37)	(−0.67, 0.84)	(−0.20, 1.31)
p-value^‡		0.902	0.575	0.885

ANCOVA analysis of covariance, CI confidence interval, IOP intraocular pressure, LS least square, PP per protocol, SEM standard error of the mean.
*Adjusting for baseline IOP (covariate) with dose group and center as factors.
^†Higher concentration minus latanoprost 50 μg/mL; a negative difference in LS mean indicates that the higher concentration has a greater effect than latanoprost 50 μg/mL.
^‡One-sided p-value.

ISSN: 1471-2415